Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.80
    +0.76 (+3.99%)

    Market Cap: $3.48B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(10/25)
    Avg Surprise
    -59.29%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.01
    Range$0.01 - $0.01
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.10-90.0%
    60d ago$0.10-90.0%
    30d ago$0.010.0%
    7d ago$0.010.0%
    Current$0.01
    Revenue Consensus
    $359M
    Range$341M - $379M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.13
    1 analysts
    Revenue Consensus
    $414M
    Range$374M - $457M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$0.01---
    Jun 26
    Reported Aug 11
    		$0.09$0.12-25.00%Miss+113.2%
    Mar 26
    Reported May 12
    		$-0.15$0.01-1113.51%Miss+72.2%
    Dec 25
    Reported Mar 10
    		$-0.16$-0.19+15.79%Beat-214.3%
    Sep 25
    Reported Nov 12
    		$-0.22$-0.18-22.22%Miss+67.6%
    Jun 25
    Reported Aug 11
    		$-0.68$-0.23-195.65%Miss-580.0%
    Mar 25
    Reported May 13
    		$-0.54$-0.34-58.82%Miss-68.8%
    Dec 24
    Reported Mar 11
    		$0.14N/A+137.24%Beat+117.5%
    Sep 24
    Reported Nov 12
    		$-0.68$-0.60-13.33%Miss-100.0%
    Jun 24
    Reported Aug 9
    		$-0.10N/A+76.19%Beat+91.2%
    Mar 24
    Reported May 13
    		$-0.32$-0.32+0.00%Beat+52.9%
    Dec 23
    Reported Mar 11
    		$-0.80$-0.83+3.61%Beat+2.4%
    Sep 23
    Reported Nov 20
    		$-0.34N/A+54.05%Beat+61.8%
    Jun 23
    Reported Aug 15
    		$-1.14$-0.83-37.35%Miss-245.5%
    Mar 23
    Reported May 18
    		$-0.68$-0.72+5.56%Beat-38.8%
    Dec 22
    Reported Mar 30
    		$-0.82$-0.56-46.43%Miss-173.3%
    Sep 22
    Reported Nov 3
    		$-0.89$-0.63-41.27%Miss-3.5%
    Jun 22
    Reported Aug 5
    		$-0.33$-0.31-6.38%Miss+50.0%
    Mar 22
    Reported Jun 1
    		$-0.49$-0.51+3.92%Beat-63.3%
    Dec 21
    Reported Mar 18
    		$-0.30$-0.41+26.83%Beat+31.8%
    Sep 21
    Reported Nov 16
    		$-0.86$-0.66-30.30%Miss-72.0%
    Jun 21
    Reported Aug 23
    		$-0.66$-0.43-53.49%Miss-29.4%
    Mar 21
    Reported May 18
    		$-0.30$-0.35+14.29%Beat+41.2%
    Dec 20
    Reported Mar 18
    		$-0.44$-0.30-46.67%Miss+31.0%
    Sep 20
    Reported Nov 16
    		$-0.50$-0.34-47.06%Miss-80.2%
    Jun 20
    Reported Aug 28
    		$-0.51$-0.28-82.14%Miss-77.5%
    Mar 20
    Reported Jun 8
    		$-0.51$0.00N/AMiss-311.3%
    Dec 19
    Reported Dec 31
    		$-0.64N/AN/ABeat-
    Sep 19
    Reported Sep 30
    		$-0.28N/AN/ABeat-
    Jun 19
    Reported Jun 30
    		$-0.29N/AN/ABeat-
    Mar 19
    Reported Mar 31
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-45.00EV/EBITDAN/A
    Price/FCF-15.01xFCF Yield-6.66%
    Profitability
    Profit Margin-7.20%Operating Margin14.90%
    ROE-8.08%ROIC-2.86%
    Financial Health
    Debt/Equity0.23xInterest Coverage-2.56x
    Current Ratio3.04xQuick Ratio2.94x
    Trading Statistics
    Beta0.57Avg Volume2.23M
    52-Week High$37.5052-Week Low$16.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.70
    SMA 20$18.75
    SMA 50$19.73
    SMA 200$22.25
    EMA 10$18.82
    EMA 20$18.91
    EMA 50$19.98
    EMA 200$23.37

    MACD

    Line: -0.24Signal: -0.38Hist: 0.14

    ADX

    ADX: 17.2+DI: 24.8-DI: 23.9

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down16.0
    PSAR$17.60

    Bollinger Bands

    Upper Band$19.91
    Lower Band$17.60
    %B Position1234%(Upper)
    Band Width0.95

    RSI (14-Day)

    Neutral
    55.3

    Momentum Oscillators

    Stoch %K55.2
    Stoch %D32.9
    Williams %R-8.2
    ROC (10d)2.5%
    Momentum0.48
    CCI (20d)142.7
    MFI (14d)48.8

    Volatility Measures

    ATR (14d)$0.95(4.8%)
    StdDev (20d)0.58
    Hist Vol49.3%(High)

    Volume Flow

    VWAP$19.52
    OBV-76.2M
    AD Line-60.5M
    CMF (20d)0.068

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.7x
    VWMA (20d)$18.72

    Pivot Points

    R3$21.92
    R2$20.83
    R1$19.93
    Pivot Point$18.84
    S1$17.95
    S2$16.85
    S3$15.96

    Advanced Oscillators

    TSI-7.14
    Ultimate Osc53.4
    KST-42.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$387.50M$305.10M$306.38M$272.33M$255.06M$195.05M$186.52M$160.21M$186.52M$93.99M$79.46M$96.01M
    Cost of Revenue$137.40M$175.90M$123.46M$115.31M$97.99M$71.34M$73.92M$55.47M$50.45M$54.74M$32.45M$48.65M
    Gross Profit$250.10M$129.20M$182.92M$157.02M$157.07M$123.71M$112.60M$104.74M$136.07M$39.25M$47.01M$47.36M
    Operating Expenses$192.40M$179.00M$203.52M$200.48M$178.95M$174.36M$187.00M$174.79M$178.04M$157.12M$166.86M$139.89M
    R&D$96.00M$85.96M$101.33M$113.15M$98.30M$101.92M$104.43M$95.52M$112.63M$100.96M$105.68M$95.86M
    SG&A$33.00M$40.00M$37.02M$34.72M$32.59M$31.46M$34.20M$35.30M$35.35M$31.93M$28.71M$28.10M
    Operating Income$57.70M$-49,800,000$-20,602,000$-43,452,000$-21,881,000$-50,647,000$-74,395,000$-70,050,000$-41,970,000$-117,864,000$-119,850,000$-92,523,000
    Interest Income$5.60M$7.30M$7.95M$9.66M$10.43M$12.06M$13.65M$16.63M$17.05M$13.87M$17.30M$18.42M
    Interest Expense$200,000$5.50M$5.48M$5.64M$5.24M$5.06M$5.15M$5.50M$5.48M$5.47M$5.82M$5.68M
    Income Before Tax$55.50M$-53,100,000$-19,599,000$-39,073,000$-124,798,000$-99,130,000$40.51M$-120,886,000$-17,970,000$-59,788,000$-146,812,000$-62,495,000
    Income Tax Expense$22.30M$1.20M$11.22M$616,000$582,000$1.79M$14.23M$4.43M$226,000$5,000$-1,994,000$-288,000
    Net Income$33.20M$-54,300,000$-30,815,000$-39,689,000$-125,380,000$-100,916,000$26.28M$-125,321,000$-18,196,000$-59,793,000$-144,818,000$-62,207,000
    EBITDA$69.40M$-32,000,000$-2,150,000$-33,194,000$-113,722,000$-88,870,000$52.46M$-109,910,000$-7,117,000$-48,591,000$-135,641,000$-51,648,000
    EBIT$57.70M$-47,600,000$-14,118,000$-39,073,000$-119,576,000$-94,069,000$45.66M$-115,382,000$-12,486,000$-54,313,000$-140,992,000$-56,819,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LEGN

    News

    Legend Biotech stock rises to EUR 17.60, up 3.68 percent on Nasdaq

    Legend Biotech's stock rose by 3.68 percent on Nasdaq, reaching EUR 17.60, following a positive second-quarter revenue report of USD 387.50 million. Analysts like H.C. Wainwright maintained a "Buy" rating with a target...

    ad-hoc-news.de•10/15/26•Bullish

    Legend Biotech gets FDA IND clearance for dual-targeting CAR-T therapy

    Legend Biotech has received FDA IND clearance for LB2501, a first-of-its-kind dual-targeting in vivo CAR-T therapy for relapsed or refractory B-cell malignancies. This therapy targets both CD19 and CD20 antigens and is...

    StreetInsider•10/15/26•Bullish

    FDA clears a study application for a therapy designed to make immune cells inside the body

    Legend Biotech (NASDAQ: LEGN) has received FDA clearance for its investigational new drug (IND) application for LB2501...

    Stock Titan•10/15/26•Neutral

    FDA Grants IND Approval to Legend Biotech for LB2501 Dual-Targeting CAR-T Therapy

    Legend Biotech Corporation announced that the FDA has approved its Investigational New Drug application for LB2501...

    Kalkine Media•10/15/26•Bullish

    H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales

    H.C. Wainwright has reiterated a Buy rating and a $65.00 price target for Legend Biotech Corp. (NASDAQ: LEGN) following better-than-expected third-quarter sales of its Carvykti treatment. The firm raised its revenue...

    Investing.com•10/15/26•Bullish

    LEGN Valuation and Fair Value

    P/E
    -45.0x
    Forward P/E
    27.6x
    P/FCF
    -15.0x
    P/B
    3.1x
    See GNG's fair value

    LEGN Profitability: Margins, ROIC and FCF

    Gross margin
    56.6%
    Operating margin
    14.9%
    Net margin
    -7.2%
    ROIC
    -2.9%
    ROE
    -8.1%
    FCF margin
    -20.1%
    FCF yield
    -6.7%

    LEGN Competitors

    CompanyTicker
    Veracyte IncVCYT
    Pulse Biosciences IncPLSE
    iRhythm Technologies IncIRTC
    Cidara Therapeutics IncCDTX
    Organon & CoOGN
    Viking Therapeutics IncVKTX
    National HealthCare CorporationNHC
    CareDx IncCDNA

    Sector: Healthcare

    LEGN Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    5
    Buy
    3
    Hold
    5
    Sell
    0
    Strong Sell
    0

    LEGN Bull Case vs Bear Case

    Bull case

    • LEGN grew quarterly revenue 51.9% year over year.
    • 61.5% of LEGN's analyst ratings are Buy or Strong Buy.

    Bear case

    • LEGN has a -7.2% net profit margin.
    • LEGN beat EPS estimates in 25.0% of its last 8 reported quarters.

    LEGN Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -159.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About LEGN

    Does LEGN pay dividends?

    Legend Biotech Corp (LEGN) does not currently pay a regular dividend.

    What is LEGN's market cap?

    Legend Biotech Corp (LEGN) has a market capitalization of $3.48B with a current stock price of $19.80.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In